🇰🇷

US Tariffs on Pharmaceutical Products from South Korea — 10% (2026)

Tariff Rate Breakdown

10%

Section 122 Base

10%

Total Effective Rate

KORUS — qualifying goods may enter duty-free

The United States imports substantial quantities of pharmaceutical products from South Korea, with approximately $169B in total bilateral trade.

The current tariff framework for pharmaceutical products from South Korea reflects the post-SCOTUS landscape: a 10% Section 122 tariff replaced the previously higher IEEPA rates after the Court's February 2026 ruling.

The Section 122 tariff is subject to a 150-day statutory time limit and is set to expire approximately July 24, 2026, unless Congress acts to extend or replace it. Importers should monitor legislative developments closely as this deadline approaches.

Pharmaceutical Products (HTS Chapter 30) generally enter duty-free at the MFN level, with the Section 122 tariff as the primary duty. No additional Section 232 or Section 301 surcharges apply to most products in this category from South Korea.

South Korea is party to the KORUS, which may provide preferential or duty-free access for qualifying pharmaceutical products. Importers should verify rules of origin requirements to take advantage of preferential rates.

Key products in HTS Chapter 30 imported from South Korea include Vaccines, Antibiotics, Insulin, Bandages, Diagnostic reagents, and Blood products.

Common Products in Chapter 30

VaccinesAntibioticsInsulinBandagesDiagnostic reagentsBlood productsPharmaceutical dosage formsFirst-aid kits

Calculate Your Import Duty

Use our tariff calculator to estimate the exact duty on your pharmaceutical products imports from South Korea.

Open Tariff Calculator

Frequently Asked Questions

What is the current tariff rate on pharmaceutical products from South Korea?

As of March 2026, pharmaceutical products from South Korea face a base tariff of 10% under Section 122. The effective rate can be up to 10%.

Will the tariff on pharmaceutical products from South Korea change?

The Section 122 tariff of 10% expires approximately July 24, 2026, unless Congress extends it. Monitor legislative developments for updates.

How did the Supreme Court ruling affect pharmaceutical products imports from South Korea?

The Supreme Court's February 20, 2026 ruling struck down IEEPA reciprocal tariffs as exceeding presidential authority. The president signed a replacement 10% tariff under Section 122 the same day, effective February 24. Qualifying goods under KORUS may still enter duty-free.